Joseph C. Papa - 31 Mar 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ Charles Schoch, as Attorney-In-Fact for Joseph C. Papa
Issuer symbol
CADL
Transactions as of
31 Mar 2026
Net transactions value
$0
Form type
4
Filing time
02 Apr 2026, 17:10:45 UTC
Previous filing
05 Mar 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Joseph C. Papa filed Form 4 for Candel Therapeutics, Inc. (CADL) on 02 Apr 2026."

Quick Takeaways

  • This page summarizes Joseph C. Papa's Form 4 filing for Candel Therapeutics, Inc. (CADL).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 02 Apr 2026, 17:10.

What Changed

  • Previous filing in this sequence was filed on 05 Mar 2026.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PAPA JOSEPH C Director C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM /s/ Charles Schoch, as Attorney-In-Fact for Joseph C. Papa 02 Apr 2026 0001242215

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Stock Option (Right to Buy) Award +2,795 $4.11* 2,795 31 Mar 2026 Common Stock 2,795 $4.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Sponsored